CARNITINE EFFECTS ON SERUM AND PANCREAS INFLAMMATORY RESPONSE IN DIABETIC RATS

Y. MASOUMI-ARDAKANI1, H. FALLAH2, B. SHAHOUZEHI1✉

1Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran;
2Student Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran;
3Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran;
✉e-mail: bshahouzehi@yahoo.com, bshahouzehi@gmail.com

Received: 08 May 2019; Accepted: 18 October 2019

Diabetes is a group of disorders characterized by elevated blood glucose and insulin secretion defect. Previous studies have reported L-carnitine beneficial and hypoglycemic effects in diabetic models. L-carnitine anti-inflammatory properties in diabetes were not assessed perfectly, and there is a lack of information about this matter. Therefore, we designed this study and evaluated L-carnitine different doses supplementation on pro-inflammatory cytokines in STZ-induced diabetic rats’ pancreas and serum. We selected 48 male rats (200 ± 10 g) and randomly divided them into six groups (n = 8). Group 1, control; group 2, Diabetic control (DC); groups 3-6, STZ-induced diabetic rats which received L-carnitine different doses as follow; 300, 200, 100 and 50 mg/kg/day by intraperitoneal injection for 5 weeks. When the study ended, serum and pancreas samples were collected and cytokines levels were measured by specific ELISA kits. Our results showed that in diabetic rats, pro-inflammatory cytokines levels were elevated. Two L-carnitine doses 300 and 200 mg/kg/day showed beneficial effects and 300 mg/kg/day showed more effective and significant effects than other doses. The 300 mg/kg significantly reduced IL-1β and IL-6 levels in pancreas and serum. Our data proved the protective effects of intraperitoneal L-carnitine administration against diabetes and inflammation in diabetic rats. Indeed, L-carnitine long term supplementation through the intraperitoneal injection can be considered as a good and safe therapeutic strategy in diabetes.

Keywords: L-carnitine, IL-1β, IL-6, TNF-α, diabetic rat.
β-cell inflammatory process, oxidative stress and dysfunction [12, 13]. Pancreatic β-cell responds to long exposure to FFA and hyperglycemia by promoting the expression of inflammatory cytokines. FFAs are able to promote IL-1β and IL-6 secretion and long exposure of pancreatic β-cell to these inflammatory agents lead to free radical activation and β-cell apoptosis [2, 8]. It seems that IL-1 is highly involved in the β-cell inflammatory process. Cytokines from other sources such as immune cells and adipose tissue also are contributed to the β-cell inflammatory process in diabetes. TNF-α is one of these cytokines which affects lipid and carbohydrate metabolism [7]. It has been reported that circulating IL-6 levels is elevated in subjects with insulin resistance and also it can be considered as a predictor of diabetes development [7].

Carnitine (3-hydroxy-4-N-trimethylaminobutyrate) is an endogenous nonessential amino acid. L-carnitine is the active form of carnitine which is synthesized from amino acids methionine and lysine in liver and kidney; also, it can be obtained from the diet [14]. Because L-carnitine has an important responsibility in intermediary metabolism, its levels in tissue and plasma is regulated at a restricted range [3]. Several studies investigated antidiabetic effects of L-carnitine and showed its hypoglycemic effects in diabetic rats [3, 15-17]. L-carnitine is able to undertake inflammation and its anti-inflammatory properties were reported previously [18, 19]. In a case-control study, Lee and colleagues investigated L-carnitine anti-inflammatory properties of L-carnitine in CAD patients. They found that L-carnitine administration (1 gr/d) reduced inflammation in patients with CAD after 12 weeks [20]. Also, there are investigations which have reported protective and beneficial effects of carnitine administration against pancreatic toxicity and pancreatitis in human studies as well as in animal models [21-23]. The route of L-carnitine administration to animal models was different (oral, intraperitoneal, subcutaneous, and intravenous). Indeed, L-carnitine quantity which used was different between previous researches. Also, there was no study which evaluated L-carnitine effects on pro-inflammatory cytokines in diabetic models. Duranay et al. and Calo and colleagues have reported anti-inflammatory properties of L-carnitine [18, 19]. Duranay et al. evaluated 3 times/weeks L-carnitine effects in hemodialysis patients, which significantly reduced CRP in these patients [18]. Calo et al. found that L-carnitine, in endothelial cell culture in presence of hydrogen peroxide, stimulates heme oxygenase-1 (HO-1) and NO synthase (HO-1 and NO synthase has anti-inflammatory, anti-oxidant and anti-proliferative properties) [19]. Therefore, we aimed to evaluate the effect of different doses of L-carnitine on blood glucose and pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) in serum and pancreas tissue of STZ-induced diabetic rats.

**Materials and Methods**

**Materials.** Streptozotocin (STZ; S0130), L-carnitine (C0283) were supplied from Sigma. IL-1 β (BMS630), IL-6 (BMS625) and TNF-α (BMS622) ELISA kits were purchased from eBioscience Company.

**Methods.** All the animal experiments were performed in accordance with the requirements of the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes (Strasbourg, 1986). L-carnitine was dissolved in PBS, pH 7.4, and introduced to diabetic rats by intraperitoneal injections at different doses. STZ was dissolved in citrate buffer (pH 4.5, 0.1 N) and administrated to animals by intraperitoneal injection. We purchased 48 male Wistar rats (200±10 g weight) from Physiology Research Center Animal Care Center. After 7 days acclimatization to a new environment, animals were randomly divided into 6 groups (n = 8). Groups were prepared as follow: group 1, control (CTR) which received no treatment; group 2, diabetic control group (DC) received a single intraperitoneal injection of STZ (50 mg/kg) to induce diabetes; group 3-6, diabetic rats (diabetes-induced as group 2) which received different doses of L-carnitine (300, 200, 100 and 50 mg/kg/day L-carnitine by i.p. injection) for 5 weeks, respectively.

Diabetes was induced in fasted (10 h) rats by intraperitoneal injection of 50 mg/kg of STZ. Three days after STZ injection, the animal were fasted overnight (10 h) and the blood samples were collected from tail vein and fasting blood glucose (FBG) were measured by glucometer (Accu-Chek, Roche, Germany) and animals with FBG > 250 mg/dl were entered to the study as diabetic animals [12, 24]. At the end of the study, the 10 h fasted animals, were decapitated under deep anesthesia and blood samples were collected and pancreas tissue was dissected and frozen immediately in liquid nitrogen and stored at -80 °C until further examination [24].
Measurement of pro-inflammatory cytokines. Pancreas samples of animals were sonicated and homogenized by Ultrasonic Processor (Hielscher, UP200H) in cold PBS with pH=7.4. The homogenized samples were centrifuged 15 min at 4 °C (15000 rpm) and then the supernatants were collected and IL-1β, IL-6 and TNF-α were quantified by ELISA method [24, 25]. Measurement of IL-1β, IL-6 and TNF-α was performed by specific kits which are based on ELISA sandwich formation. In each kit, the first specific antibody is coated at ELISA wells and this antibody is dependent on which cytokine is going to be detected. After serum or supernatant loading into the wells and incubation, the next step is washing which followed by second antibody addition to the reaction mixture which results in ELISA sandwich formation and then yellow color generated after the addition of stop solution. Finally, the reaction color development in wells is measured at 450 nm by ELISA late reader [25, 26].

Statistical analysis. All data are expressed as Mean ± SEM. Data analysis was performed by one-way ANOVA test followed by post hocTukey’s to compare mean differences between groups. The P < 0.05 was considered as statistically significant.

Results and Discussion

The diabetic control group (STZ-induced diabetic rats) showed significant elevation of glucose, serum and pancreas values of IL-1β (Table, Fig. 1, A, Fig. 2, A), IL-6 (Fig. 1, C, Fig. 2, C), pancreas TNF-α (P < 0.001) (Fig. 1, B), serum TNF-α (P = 0.004) (Fig. 2, B) compared to control group.

Administration of 300 mg/kg/day of L-carnitine significantly reduced serum glucose, pancreas IL-1β (Fig. 1, A) and also serum IL-1β and IL-6 levels (P < 0.001) (Fig. 2, A and C). Administration of 200 mg/kg/day of L-carnitine significantly reduced glucose levels (P < 0.001), serum IL-1β (P = 0.017) (Fig. 2, A) and pancreas IL-1β and IL-6 values (P < 0.01) (Fig. 1, A and C) compared to DC group. Supplementation of 200 mg/kg/day of L-carnitine was not as effective as 300 mg/kg/day of L-carnitine. Low doses of L-carnitine (50 and 100 mg/kg/day) did not show any significant effects.

Our results showed that L-carnitine i.p. administration has valuable effects which attenuated pro-inflammatory cytokines levels in pancreas and serum of STZ-induced diabetic rats. Also, we found that 300 mg/kg/day of L-carnitine is very effective compared to other doses we administrated in this study.

Intraperitoneal administration of 600 mg/kg/day of L-carnitine attenuated serum glucose, and lipid profile in a rat model of type 2 diabetes [27]. Previously, we showed that 600 mg/kg/day of oral L-carnitine administration (5 weeks) reduced serum glucose and normalized insulin in STZ-induced diabetic rats [15]. Other studies also evaluated the therapeutic effects of L-carnitine in diabetic models [15, 27, 28]. We found that high doses of L-carnitine (200 and 300 mg/kg/day; i.p. administration) decreased serum glucose levels. L-carnitine glucose-lowering effects in diabetes is controversial. Several studies showed glucose-lowering effect upon L-carnitine administration but some other studies were not successful to show this hypoglycemic property of L-carnitine [15, 27, 29-32]. This controversy could be contributed to the route of L-carnitine administration in different studies. This is obvious that the studies in which L-carnitine was introduced by i.p. injections, they obtained more prominent and remarkable hypoglycemia compare to studies which administrated L-carnitine orally. Also, those studies used a lower dosage of L-carnitine compared to studies which administrated L-carnitine orally.

Inflammation is involved in apoptosis, dedifferentiation and malfunction of β-cell [33, 34]. Chronic inflammation compromised β-cell insulin secretion and IL1β, IL-6, TNF-α and interferons have shown potent deleterious effects on β-cells function [34]. In the case of reduced insulin secretion, it was reported that IL-1β showed strong det-

### Anti-hyperglycemic effect of different doses of L-carnitine in diabetic rats’ serum

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Animal groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose, mg/dl</td>
<td>CTR</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>91.0 ± 3.2*</td>
</tr>
</tbody>
</table>

The data are expressed as mean±SEM; *P < 0.05 was considered as significant. *Statistically significant compared to control group; †statistically significant compared to diabetic group. Control (CTR), diabetic control (DC).
Cytokines values in pancreas tissue measured by ELISA method in studied groups which were as follow; CTR group, untreated control; DC, Diabetic control group (received single dose of 50 mg/kg of STZ); group III-VI, diabetic groups which received different doses of L-carnitine (50, 100, 200 and 300 mg/kg/day) by i.p. injection for 5 weeks. Fig. A showed IL-1β, Fig. B showed TNF-α and Fig. C showed IL-6 levels in each groups. P < 0.05 was considered as significant. The data are expressed as Mean±SEM, *statistically significant compared to CTR group, and #statistically significant compared to DC group.

Fig. 1. Cytokines values in pancreas tissue measured by ELISA method in studied groups which were as follow; CTR group, untreated control; DC, Diabetic control group (received single dose of 50 mg/kg of STZ); group III-VI, diabetic groups which received different doses of L-carnitine (50, 100, 200 and 300 mg/kg/day) by i.p. injection for 5 weeks. Fig. A showed IL-1β, Fig. B showed TNF-α and Fig. C showed IL-6 levels in each groups. P < 0.05 was considered as significant. The data are expressed as Mean±SEM, *statistically significant compared to CTR group, and #statistically significant compared to DC group.

This is well documented that pro-inflammatory cytokines such as IL-1β, interferon-γ (IFN-γ) and TNF-α are involved in diabetes especially T1D, and IL-1β result in β-cell death. IL-1β triggers the processes by NF-kB which final effect is apoptosis induction in pancreatic β-cell [9, 11]. The L-carnitine effects on pro-inflammatory cytokines in serum and pancreas of STZ-induced diabetic models were not studied well enough. Two studies in 2006 by Duranay et al. and Calo et al., investigated anti-inflammatory effects of L-carnitine [18, 19]. Duranay and colleagues have revealed CRP reducing effects of L-carnitine (3 times/weeks) [18], on the other hands, Calo and colleagues in their in vitro study showed that L-carnitine anti-inflammatory effects which was conducted through induction of HO-1 and NO synthase in endothelial cell culture [19]. Our finding revealed that confirmed pro-inflammatory cytokines levels were increased in STZ-induced diabetic rats compared to the control group. L-carnitine administration showed an important effect against pro-inflammatory cytokines elevation in diabetic rats. Hussein et al. showed that oral L-carnitine (300 mg/kg, 2 months) administration in high fructose diet rats normalized serum TNF-α and IL-6 levels [12]. Their findings are the same as our results which confirm L-carnitine effects which reduced IL-1β, IL-6 and TNF-α in serum and pan-

rimental effects than IL-6 and TNF-α [34].
Y. Masoumi-Ardakani, H. Fallah, B. Shahouzehi

Fig. 2. Serum cytokines levels, measured by ELISA method in studied groups which were as follow: CTR group, untreated control; DC, Diabetic control group (received single dose of 50 mg/kg of STZ); group III-VI, diabetic groups which received different doses of L-carnitine (50, 100, 200 and 300 mg/kg/day) by i.p. injection for 5 weeks. Fig. A showed IL-1β, Fig. B showed TNF-α and Fig. C showed IL-6 levels in each groups. P < 0.05 was considered as significant. The data are expressed as Mean±SEM, *statistically significant compared to CTR group, and #statistically significant compared to DC group.

IL-1β has an important role in β-cell function and survival in human and rodents [9]. We found that 300 and 200 mg/kg L-carnitine reduced serum and pancreas IL-1β levels. Therefore, it seems that attenuation of IL-1β levels can be considered as an important way by which L-carnitine exerts its beneficial effects in diabetic rats. TNF-α is an important pro-inflammatory cytokine which affects the metabolism of lipid and glucose. Also, it was reported that TNF-α is related to insulin resistance. TNF-α increases FFA and attenuates insulin signaling, it also affects insulin secretion and signaling [7]. These reports direct us to the idea that L-carnitine reduces insulin resistance state in diabetes and exerts insulin sensitizing effects through reducing TNF-α level. On the other hands, it has been reported that IL-6...
is elevated along with insulin resistance. Also, elevated serum IL-1 and IL-6 levels are contributed to diabetes mellitus occurrence[7]. L-carnitine attenuates serum IL-1 and IL-6 levels by reducing glucose and lipid toxicity in serum and pancreas and also by the improvement of anti-oxidant states, therefore it reduces pro-inflammatory cytokines and inflammation in diabetic models.

Conclusion. L-carnitine anti-oxidant and hypo-glycemic effects in diabetic models confirm its protective effects in diabetic models. Adiponectin and AMPK are considered as insulin-sensitizing proteins which mimic insulin effects in the body. In our previous study, we found that L-carnitine supplementation increased AMPK expression and serum levels of adiponectin, therefore, it seems that L-carnitine hypoglycemic properties in this model which lost their almost 90% of islet beta-cells was contributed to indirect insulin sensitizing effects of L-carnitine. On the other hands, L-carnitine increases lipid beta-oxidation and reduces lipid levels in cells and probably promotes insulin effectiveness. These protective effects maintain homeostasis and protect tissue and organs from more injuries and finally, it can lower inflammatory response in diabetes. Also, L-carnitine i.p. administration is more effective than oral administration and its dose of administration is important to see the best action of L-carnitine in animal models. On the other hands, the duration of the study is also important. The longer the treatment lasts the more effective L-carnitine function we can observe.

Acknowledgements. This research was financially supported by Kerman Medical University Research Council and Physiology Research Center.

Conflict of interest. Authors have completed the Unified Conflicts of Interest form at http://ukrbiochemjournal.org/wp-content/uploads/2018/12/coi_disclosure.pdf and declare no conflict of interest.
позитивні ефекти, при цьому ефект від введения L-карнітину в дозі 300 мг/кг на добу був значнішим. L-карнітин у дозі 300 мг/кг на добу істотно знижував вміст IL-1β і IL-6. У підшлунковій залозі і сироватці крові. Одержані результати підтвердили захисний ефект інтратерапіонельно введеного L-карнітину у разі запалення в діабетичних щурів. Отже, введення L-карнітину протягом тривалого часу можна розглядати як ефективну і безпечну терапевтичну стратегію за діабету.

Ключові слова: L-карнітин, IL-1β, IL-6, TNF-α, діабетичні щури.

References


